Publication details

An in silico molecular dynamics simulation study on the inhibitors of SARS-CoV-2 proteases (3CLpro and PLpro) to combat COVID-19

Authors

BERA Krishnendu REEDA V. S. Jeba BABILA P. R. DINESH Dhurvas Chandrasekaran HRITZ Jozef KARTHICK Thangavel

Year of publication 2021
Type Article in Periodical
Magazine / Source Molecular Simulation
Citation
Web https://doi.org/10.1080/08927022.2021.1957884
Doi http://dx.doi.org/10.1080/08927022.2021.1957884
Keywords SARS-CoV-2 PLpro; SARS-CoV-2 3CLpro inhibitors; molecular docking; molecular dynamics simulation; MM/PBSA
Description The work attempts to recognise the possible inhibitors against Papain-like protease (PLpro) and 3-Chymotrypsin-like protease (3CLpro) of SARS-CoV-2 to combat infectious COVID-19 virus using in silico studies. These two proteases are predominantly involved in the virus replication cycle; hence they are considered as potential drug targets. The virtual dock screening was performed for 53 selected drugs. The drugs with higher binding energy and oriented in the vicinity of active binding sites were selected for finding thermal stability using molecular dynamics (MD) simulation. The docking result reflects that the drugs A17 (Dasabuvir) and A34 (Methisazone) bind with PLpro and the drugs A17 and A53 (Vaniprevir) bind with 3CLpro with higher binding affinities. The MD simulation and principal component analysis show that the drug A17 has stable dynamic behaviour with both proteins over the 300 ns time-scale. The binding free energy of complexes was predicted from the last 100 ns trajectories using MM/PBSA. The predicted binding free energy of PLPro-A17 (Dasabuvir) and PLpro-A34 complexes (Methisazone) were -16.1 kcal/mol and -12.3 kcal/mol, respectively and -41.3 kcal/mol and -11.9 kcal/mol for 3CLpro-A17 (Dasabuvir) and 3CLpro-A53 (Vaniprevir) complexes, respectively. However, further experimental validation is required to confirm their inhibitory activities against SARS-CoV-2 causing COVID-19.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info